Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market.
Iran
Myozyme
Pompe disease
cost-effectiveness
enzyme replacement therapy
Journal
Intractable & rare diseases research
ISSN: 2186-3644
Titre abrégé: Intractable Rare Dis Res
Pays: Japan
ID NLM: 101586847
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
ppublish
Résumé
Infantile-onset Pompe disease (IOPD) or acid maltase deficiency is a rare metabolic disorder. It is caused by a deficiency in functioning of the enzyme acid alpha-glucosidase and leads to the accumulation of glycogen in the liver, heart, muscle, and other tissues. Myozyme is an effective drug, but it imposes a heavy financial burden on societies and healthcare systems. Therefore, this study was conducted to analyze the cost-effectiveness of Myozyme compared to conventional therapy for the treatment of IOPD. PubMed, Scopus, Web of Science, and Cochrane library databases were searched on December 2018 to identify the effectiveness of Myozyme versus conventional therapy. Then, a cost-effectiveness and a cost utility study were conducted in patients suffering from IOPD. In this cost effectiveness and cost utility analysis, Markov and decision tree models were used for modeling. Model parameters were obtained from international data, and the perspective of the payer was considered. Every cycle was one year; the model was run for 22 cycles. TreeAge pro 2011 was used for analysis. Finally, one-way and probabilistic sensitivity analyses were performed. Two papers were included and 39 patients were evaluated as the treatment group in both studies. Results revealed the effectiveness of Myozyme. Results also revealed a wide range of adverse reactions. Enzyme replacement therapy (ERT) resulted in 4.21038 quality-adjusted life years (QALY) per $381,852. The incremental cost per QALY was $96,809 and the incremental cost per life years gained (LYG) was 74,429 over a 22-year time horizon. Sensitivity analysis indicated the robustness of the results. Myozyme is effective for IOPD and could increase the life expectancy of patients significantly. However, since the calculated incremental cost per QALY was 17 times higher than the GDP per capita of Iran, Myozyme is not cost effective in Iran.
Identifiants
pubmed: 32844068
doi: 10.5582/irdr.2020.03028
pmc: PMC7441026
doi:
Types de publication
Journal Article
Langues
eng
Pagination
130-136Informations de copyright
2020, International Research and Cooperation Association for Bio & Socio - Sciences Advancement.
Références
J Inherit Metab Dis. 2014 Nov;37(6):945-52
pubmed: 24906254
Eur J Neurol. 2017 Jun;24(6):768-e31
pubmed: 28477382
J Shoulder Elbow Surg. 2010 Mar;19(2):258-61
pubmed: 19574063
Iran Red Crescent Med J. 2016 Oct 02;18(11):e37094
pubmed: 28203449
Mol Genet Metab. 2017 Mar;120(3):163-172
pubmed: 28185884
Rev Salud Publica (Bogota). 2012 Jan-Feb;14(1):143-55
pubmed: 23250322
J Inherit Metab Dis. 2011 Oct;34(5):1045-52
pubmed: 21499718
Neurology. 2007 Jan 9;68(2):99-109
pubmed: 17151339
Mol Genet Metab. 2016 Feb;117(2):114-9
pubmed: 26454691
J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S333-9
pubmed: 20821053
Orphanet J Rare Dis. 2014 May 16;9:75
pubmed: 24884717
Lancet. 2008 Oct 11;372(9646):1342-53
pubmed: 18929906
J Inherit Metab Dis. 2012 Sep;35(5):837-45
pubmed: 22290025
Bull World Health Organ. 2016 Dec 1;94(12):925-930
pubmed: 27994285
Mol Genet Metab. 2012 Nov;107(3):469-79
pubmed: 23041258
J Clin Pharm Ther. 2015 Jun;40(3):304-7
pubmed: 25891411
Circ Cardiovasc Genet. 2016 Feb;9(1):6-13
pubmed: 26787432
Clin Neurol Neurosurg. 2011 May;113(4):303-7
pubmed: 21216089
Pharmacoecon Open. 2020 Mar;4(1):79-90
pubmed: 31168754
Eur J Health Econ. 2009 Oct;10(4):357-9
pubmed: 19618224
Genet Med. 2009 Mar;11(3):210-9
pubmed: 19287243
JIMD Rep. 2015;19:67-73
pubmed: 25681082
Pediatrics. 2003 Aug;112(2):332-40
pubmed: 12897283
Can Respir J. 2002 May-Jun;9(3):169-77
pubmed: 12068338
Muscle Nerve. 2009 Jul;40(1):149-60
pubmed: 19533647
BMJ. 1993 Sep 18;307(6906):726-8
pubmed: 8401098
J Med Econ. 2018 Mar;21(3):282-287
pubmed: 29105528